Objective To compare educational, occupational, legal, emotional, substance use disorder, and sexual-behavior outcomes in young adults with persistent and desistent attention-deficit/hyperactivity disorder (ADHD) symptoms and a local normative comparison group (LNCG) in the Multimodal Treatment Study of Children with ADHD (MTA). Method Data were collected 12, 14, and 16 years post-baseline (mean age 24.7 years at 16 years post-baseline) from 476 participants with ADHD diagnosed at age 7–9, and 241 age- and sex-matched classmates. Probands were subgrouped on persistence vs. desistence of DSM-5 symptom count. Orthogonal comparisons contrasted ADHD vs. LNCG and Symptom-Persistent (50%) vs. Symptom-Desistent (50%) subgroups. Functional outcomes were measured with standardized and demographic instruments. Results Three patterns of functional outcomes emerged. Post-secondary education, times fired/quit a job, current income, receiving public assistance, and risky sexual behavior showed the most common pattern: the LNCG fared best, Symptom-Persistent ADHD worst, and Symptom-Desistent ADHD between, with largest effect sizes between LNCG and Symptom-Persistent ADHD. In the second pattern, seen with emotional outcomes (emotional lability, neuroticism, anxiety disorder, mood disorder) and substance use outcomes, the LNCG and Symptom-Desistent ADHD did not differ, but both fared better than Symptom-Persistent ADHD. In the third pattern, noted with jail time (rare), alcohol use disorder (common), and number of jobs held, group differences were not significant. The ADHD group had 10 deaths compared to one in the LNCG. Conclusion Adult functioning after childhood ADHD varies by domain and is generally worse when ADHD symptoms persist. It is important to identify factors and interventions that promote better functional outcomes.

BACKGROUND: The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7–10 years of age) diagnosed with ADHD-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2 to 16 years after baseline. METHODS: Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). In the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. RESULTS: For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51+0.04, p<0.0001, d=1.11), documenting symptom persistence, and for the parent/self-report difference (0.21+0.04, p<0.0001, d=0.60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29+0.55 cm shorter than the LNCG (p<0.01, d=0.21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55+0.73 cm shorter than the subgroup with the Negligible pattern (p< 0.0005, d=0.42), and within the treated group, the subgroup with the Consistent pattern was 2.35+1.13 cm shorter than the subgroup with the Inconsistent pattern (p<0.04, d=0.38). CONCLUSIONS: In the MTA follow-up into early adulthood, ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom-severity.

No abstract